In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Diabetica Ltd.

Start-Up Previews (12/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The Double-edged Sword of Diabetes Drug Development, features profiles of Alba Therapeutics, Alinea, DiaKine and Diabetica. Plus these Start-Ups Across Health Care: Actimis, Luminous Medical, NABsys and Pathfinder Therapeutics.

The Double-edged Sword of Diabetes Drug Development

Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.

BioPharmaceutical Regulation

Diabetica Ltd.

In contrast to a host of companies pursuing GLP-1 pathway in diabetes, Diabetica is pioneering GIP research. Because there is currently no marketed antagonist to make insulin work better in the body, as Diabetica believes its GIP agonist will, the company hopes that, at the end of the day, it won't be competing with other compounds at all.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register